diklofen 10mg/g gel
galenika crna gora d.o.o. za proizvodnju i promet farmaceutskih proizvoda - diklofenak - gel - 10mg/g
sinedol 500 i.j./g + 150 mg/g + 25 mg/g gel
hemofarm a.d. vrŠac p.j. podgorica - heparin, dimetilsulfoksid, dekspentanol - gel - 500 i.j./g + 150 mg/g + 25 mg/g
hepathrombin 300i.j./g gel
hemofarm a.d. vrŠac p.j. podgorica - heparin natrijum - gel - 300i.j./g
hepathrombin 500i.j./g gel
hemofarm a.d. vrŠac p.j. podgorica - heparin natrijum - gel - 500i.j./g
hepathrombin 1000i.j./g gel
hemofarm a.d. vrŠac p.j. podgorica - heparin natrijum - gel - 1000i.j./g
doptelet
swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenija - antihemorrhagics - doptelet naznačeno za liječenje teških тромбоцитопении kod odraslih pacijenata s kroničnom bolešću jetre, koji planiraju proći postupak инвазивную. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroidi, imunoglobulini).
pradaxa 150 mg/1 kapsula kapsula, tvrda
boehringer ingelheim bh d.o.o. - дабигатран eteksilat - kapsula, tvrda - 150 mg/1 kapsula - 1 kapsula, tvrda sadrži: 150 mg dabigatran eteksilata
pradaxa 150 mg/1 kapsula kapsula, tvrda
boehringer ingelheim bh d.o.o. - дабигатран eteksilat - kapsula, tvrda - 150 mg/1 kapsula - 1 kapsula, tvrda sadrži: 150 mg dabigatran eteksilata
clopidogrel bgr (previously zylagren)
biogaran - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - sprječavanje атеротромботических događaja klopidogrel prikazan:odrasli pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija.
clopidogrel acino
acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.